Download Image
    
Share
  
Post
Trimodulin for COVID-19
1 study with 166 patients
Hospital Icon Control
Hospital Icon Trimodulin Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Trimodulin studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies -17% Mortality -17% RCTs -17% Late -17% Favorstrimodulin Favorscontrol
Aug 13
2024
 Agafina et al., European Journal of Medical Research, doi:10.1186/s40001-024-02008-x Efficacy and safety of trimodulin in patients with severe COVID-19: results from a randomised, placebo-controlled, double-blind, multicentre, phase II trial (ESsCOVID)
17% higher mortality (p=0.7), 2% lower progression (p=1), and 9% longer ventilation (p=0.62). RCT 166 severe COVID-19 patients on non-invasive ventilation or high-flow oxygen showing no significant difference in clinical deterioration or mortality with trimodulin treatment compared to placebo. In a post hoc analysis of a subgroup ..